Latest Australian Clinical Labs (Asx:Acl) News

Australian Clinical Labs has announced a 12-month on-market share buy-back program targeting up to 10% of its shares, aiming to enhance shareholder returns without compromising its financial strength.

Australian Clinical Labs has reached a $6.2 million settlement with the Australian Information Commissioner to resolve a Federal Court case stemming from a 2022 cyberattack on its newly acquired Medlab Pathology business.

Australian Clinical Labs delivered solid FY25 financial results with revenue up 6.4% and EBIT rising 8.7%, underpinned by operational efficiencies and strategic innovation. The company’s FY26 guidance signals continued growth amid evolving market conditions and government fee pressures.

Australian Clinical Labs reported robust FY25 financial results with revenue and earnings growth, alongside a strong dividend payout and positive outlook for FY26.

Australian Clinical Labs reported a 6.4% revenue increase and an 8.7% rise in underlying EBIT for FY25, maintaining disciplined growth and operational efficiency in a complex healthcare environment.

Australian Clinical Labs reported a 6.4% revenue increase and an 8.7% rise in underlying EBIT for FY25, maintaining disciplined growth and operational efficiency in a complex healthcare environment.